In the GLP-1 era, practitioners are helping patients lose weight faster and in larger amounts than before. That makes skeletal protection increasingly important. This article examines five signals that change during weight loss—mechanical loading, estrogen, calcium balance, gut delivery, and rate—and translates them into practical considerations for screening and intervention.
The rapid global adoption of glucagon-like peptide-1 (GLP-1) receptor agonists-such as semaglutide (Ozempic®, Wegovy®) and related agents-has reshaped the pharmaceutical management of diabetes and obesity. As their use has expanded to tens of millions worldwide, post-marketing surveillance has begun to identify rare but serious adverse events that warrant careful clinical scrutiny. One emergingRead
A comprehensive plan for patients taking GLP-1s is crucial—no matter how you feel about it. When GLP-1 agonists first hit the market, frustrated Americans eagerly embraced them as a miracle cure for weight loss, obesity and diabetes. Since then, the use of GLP-1s has skyrocketed, with some data showingRead
Incidence of adult obesity has doubled in the past 25 years, with almost 1 billion people worldwide—about 1 in every 8—classified as obese in 2022. And with nearly 50% of the global adult population meeting the clinical definition of overweight, those numbers don’t show any signs of decreasing. This epidemicRead
In recent years, the pharmaceutical landscape has seen the emergence of glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) such as semaglutide and tirzepatide, offering promising outcomes in weight reduction for those struggling with obesity. Landmark trials demonstrated significant weight loss in obese individuals. In the STEP 1 and STEP 3 trials,Read
With the celebration of International Women’s Day on March 8th, it’s timely to review the differences in women’s health research and how that specifically affects investigations into treatments for overweight and obesity. Obesity and overweight—gender similarities and differences By 2022, 8 billion people over 18 (43%) were overweight globally, ofRead
According to the World Health Organization, some 55 million people globally suffer from Alzheimer’s disease or dementia. With 10 million new cases diagnosed annually, dementia has become the seventh leading cause of death worldwide, and those numbers are only likely to grow as life expectancy continues to increase. Thus far,Read
With the massive interest in the use of glucagon-like peptide-1 (GLP-1) receptor agonists for the management of both Type 2 diabetes and obesity/overweight, it is timely to review the mode of action of these medications and that of an alternative GLP-1-stimulating nutraceutical. Production of GLP-1 After a meal, endogenous GLP-1Read
A trio of studies performed in the past 5 years shows that a proprietary hops extract called Amarasate can help curb hunger and food cravings.
Blending pharmaceuticals, nutraceuticals and integrative approaches for safe, sustainable weight loss that works. Of all the challenges encountered by practitioners, helping patients achieve and maintain weight loss continues to be one of the most frustrating, futile issues. Now, a new generation of prescription drugs offer hope, but not without significantRead
